Talking Points

Vivek Reddy and C. Michael Gibson compare pulsed field ablation versus thermal ablation for patients with paroxysmal atrial fibrillation.

Mathieu Kerneis and C. Michael Gibson compare outcomes of patients treated with anakinra, a new therapy for acute myocarditis, or placebo.

Dan Jones and C. Michael Gibson discuss whether inorganic nitrate reduces contrast-induced nephropathy after angiography in ACS patients.

Zachary Cox and C. Michael Gibson discuss whether early dapagliflozin initiation is safe and effective for patients with acute heart failure.

Shaoping Nie, Gilles Montalescot, and C. Michael Gibson discuss prolonged anticoagulation after primary PCI for patients with MI.

Michael J. Reardon and C. Michael Gibson discuss the trial's 4-year results in low-surgical-risk patients with severe aortic stenosis randomized to self-expanding TAVI or SAVR.

Robert W. Yeh and C. Michael Gibson discuss the primary outcomes of this eagerly awaited trial comparing the AGENT paclitaxel-coated balloon with conventional balloon angioplasty for in-stent restenosis.

Susheel K. Kodali and C. Michael Gibson discuss transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation.

Josep Rodés-Cabau and C. Michael Gibson discuss the benefits of TAVI versus SAVR in patients with severe aortic stenosis and small aortic annuli.

A. Michael Lincoff and C. Michael Gibson discuss the cardiovascular impact of semaglutide in patients with overweight or obesity but without diabetes.

Jeffrey Carson and Serge Korjian discuss restrictive versus liberal blood transfusion in patients with MI and anemia.

Christopher Rajkumar, Rasha Al-Lamee, and C. Michael Gibson discuss this randomized trial of PCI versus a placebo procedure for stable angina.

Mandeep Mehra and C. Michael Gibson discuss whether or not aspirin is needed for patients with left ventricular assist devices in advanced heart failure.

Christian T. Ruff and C. Michael Gibson discuss the primary results of a randomized trial testing the efficacy of abelacimab versus rivaroxaban for stroke prevention in atrial fibrillation.

Andrew Bellinger, Sek Kathiresan, and C. Michael Gibson talk about the phase 1b trial of what investigators hope may be a one-time genetic fix for hyperlipidemia.

Steven Nissen and C. Michael Gibson discuss the efficacy and safety of lepodisiran, an extended duration short-interfering RNA meant to reduce lipoprotein (a).

Paul Ridker and C. Michael Gibson discuss whether residual inflammatory risk or residual cholesterol risk is a more effective predictor of CV events among patients treated with statins.

Mike Sharma and C. Michael Gibson discuss managing acute thromboembolic events in secondary stroke using antithrombotic treatment with factor XIa inhibition.

Axel Bauer and C. Michael Gibson talk about whether smartphone-based screening can effectively detect atrial fibrillation in elderly, at-risk patients.

Ganesan Karthikeyan and C. Michael Gibson compare the efficacy of rivaroxaban versus vitamin K agonists for patients with rheumatic heart disease associated atrial fibrillation

Joo-Yong Hahn and C. Michael Gibson compare FFR with angiography-guided PCI for patients with acute myocardial infarction and multivessel disease.

Marco Valgimigli and C. Michael Gibson discuss the long-term follow-up results from MASTER DAPT, which compared the outcomes of high bleeding risk patients randomized to either abbreviated or standard antiplatelet therapy.

Marco Valgimigli and C. Michael Gibson discuss the PANTHER trial, which compared P2Y12 inhibitor monotherapy with aspririn monotherapy in patients with coronary artery disease.

Giuseppe Gargiulo and C. Michael Gibson discuss whether the choice of radial or femoral artery access impacts the risk of mortality and major bleeding for patients undergoing coronary procedures.

Sanjit Jolly and C. Michael Gibson discuss if colchicine and rivaroxaban plus aspirin can slow disease progression in patients hospitalized with COVID-19.